Heparin‐induced thrombocytopenia (HIT) is a potentially catastrophic complication of heparin therapy. The syndrome is the result of the production of an antibody to the complex that forms between heparin and platelet factor 4 (H‐PF4) released from activated platelets. IgG antibodies bind to platelet Fc receptors and cause platelet activation, resulting in thrombocytopenia and greatly increased risk of thrombosis. Tests for the H‐PF4 antibody can be classified into functional assays (which rely on the demonstration of platelet activation) and immunoassays (which detect the presence of an antibody without regard for its functional ability). The functional assays have a greater specificity for clinical HIT, but require normal donor platelets and are relatively unstandardized. The immunoassays have the advantage of better standardization and do not require normal platelets, but may give positive results in the absence of clinical HIT. The choice of test is usually dictated by what is possible for a given laboratory in terms of instrumentation, expertise, and interest. For most institutions this will be a commercially available enzyme‐linked immunosorbent assay. Although HIT is a true clinicopathological syndrome, there are several reasons why its diagnosis still rests primarily on clinical grounds. First, laboratory tests may not be available locally. Second, they may not be available in a sufficiently timely manner. Finally, available tests are not completely sensitive or specific for the condition. There is, therefore, a continuing need to develop more rapid testing strategies with greater specificity for clinical HIT.
KEYWORDS
Heparin‐induced thrombocytopenia - HIT - platelet counts - heparin‐platelet factor 4 antibodies - laboratory diagnosis
REFERENCES
-
1
Kelton J G, Smith J W, Warkentin T E, Hayward C P, Denomme G A, Horsewood P.
Immunoglobulin G from patients with heparin‐induced thrombocytopenia binds to a complex of heparin and platelet factor 4.
Blood.
1994;
83
3232-3239
-
2
Chong B H, Fawaz I, Chesterman C N, Berndt M C.
Heparin‐induced thrombocytopenia: mechanism of interaction of the heparin‐dependent antibody with platelets.
Br J Haematol.
1989;
73
235-240
-
3
Chong B H.
Heparin‐induced thrombocytopenia.
J Thromb Haemost.
2003;
1
1471-1478
-
4
Warkentin T E.
Clinical presentation of heparin‐induced thrombocytopenia.
Semin Hematol.
1998;
35
9-16
-
5
Warkentin T E, Kelton J G.
Temporal aspects of heparin‐induced thrombocytopenia.
N Engl J Med.
2001;
344
1286-1292
-
6
Warkentin T E, Kelton J G.
Delayed‐onset heparin‐induced thrombocytopenia and thrombosis.
Ann Intern Med.
2001;
135
502-506
-
7
Rice L, Attisha W K, Drexler A, Francis J L.
Delayed‐onset heparin‐induced thrombocytopenia.
Ann Intern Med.
2002;
136
210-215
-
8
Warkentin T E.
Platelet count monitoring and laboratory testing for heparin‐induced thrombocytopenia.
Arch Pathol Lab Med.
2002;
126
1415-1423
-
9
Warkentin T E, Hayward C P, Smith C A, Kelly P M, Kelton J G.
Determinants of donor platelet variability when testing for heparin‐induced thrombocytopenia.
J Lab Clin Med.
1992;
120
371-379
-
10
Brandt J T, Isenhart C E, Osborne J M, Ahmed A, Anderson C L.
On the role of platelet FcgammaRIIa phenotype in heparin‐induced thrombocytopenia.
Thromb Haemost.
1995;
74
1564-1572
-
11
Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C.
Laboratory diagnosis of heparin‐associated thrombocytopenia and comparison of platelet aggregation test, heparin‐induced platelet activation test, and platelet factor 4/heparin enzyme‐linked immunosorbent assay.
Transfusion.
1994;
34
381-385
-
12
Sheridan D, Carter C, Kelton J G.
Clinical usefulness of testing for a heparin‐dependent platelet‐aggregating factor in patients with suspected heparin‐associated thrombocytopenia.
J Lab Clin Med.
1984;
103
606-612
-
13 Warkentin T E, Greinacher A. Laboratory testing for HIT. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia New York; Marcel Dekker 2001: 231-269
-
14
Harenberg J, Huhle G, Giese C et al..
Determination of serotonin release from platelets by enzyme immunoassay in the diagnosis of heparin‐induced thrombocytopenia.
Br J Haematol.
2000;
109
182-186
-
15
Koch S, Harenberg J, Odel M, Schmidt-Gayk H, Walch S, Budde U.
Development of a high‐pressure liquid chromatography method for diagnosis of heparin‐induced thrombocytopenia.
Am J Clin Pathol.
2002;
117
900-904
-
16
Gobbi G, Mirandola P, Tazzari P L et al..
Flow cytometry detection of serotonin content and release in resting and activated platelets.
Br J Haematol.
2003;
121
892-896
-
17
Stewart M W, Etches W S, Boshkov L K, Gordon P A.
Heparin‐induced thrombocytopenia: an improved method of detection based on lumi‐aggregometry.
Br J Haematol.
1995;
91
173-177
-
18
Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C.
A rapid and sensitive test for diagnosing heparin‐associated thrombocytopenia.
Thromb Haemost.
1991;
66
734-736
-
19
Warkentin T E, Hayward C P, Boshkov L K et al..
Sera from patients with heparin‐induced thrombocytopenia generate platelet‐derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin‐induced thrombocytopenia.
Blood.
1994;
84
3691-3699
-
20
Lee D H, Warkentin T E, Denomme G A, Hayward C PM, Kelton J G.
A diagnostic test for heparin‐induced thrombocytopenia: detection of platelet microparticles using flow cytometry.
Br J Haematol.
1996;
95
724-731
-
21
Tomer A.
A sensitive and specific functional flow cytometric assay for the diagnosis of heparin‐induced thrombocytopenia.
Br J Haematol.
1997;
98
648-656
-
22
Vitale M, Tazzari P, Ricci F et al..
Comparison between different laboratory tests for the detection and prevention of heparin‐induced thrombocytopenia.
Cytometry.
2001;
46
290-295
-
23
Jy W, Mao W W, Horstman L L, Valant P A, Ahn Y S.
A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin‐induced thrombocytopenia (HIT) from HIT with thrombosis (HITT).
Thromb Haemost.
1999;
82
1255-1259
-
24
Chong B H, Grace C S, Rozenberg M C.
Heparin‐induced thrombocytopenia: effect of heparin platelet antibody on platelets.
Br J Haematol.
1981;
49
531-540
-
25
Chong B H, Burgess J, Ismail F.
The clinical usefulness of the platelet aggregation test for the diagnosis of heparin‐induced thrombocytopenia.
Thromb Haemost.
1993;
69
344-350
-
26
Trossaert M, Gaillard A, Commin P L, Amiral J, Vissac A M, Fressinaud E.
High incidence of anti‐heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery.
Br J Haematol.
1998;
101
653-655
-
27
Francis J L, Palmer III G J, Moroose R, Drexler A.
Comparison of bovine and porcine heparin in heparin antibody formation after cardiac surgery.
Ann Thorac Surg.
2003;
75
17-22
-
28
Mattioli A V, Bonetti L, Sternieri S, Mattioli G.
Heparin‐induced thrombocytopenia in patients treated with unfractionated heparin: prevalence of thrombosis in a 1-year follow‐up.
Ital Heart J.
2000;
1
39-42
-
29
Williams R T, Damaraju L V, Mascelli M A et al..
Anti‐platelet factor 4/heparin antibodies: an independent predictor of 30‐day myocardial infarction after acute coronary ischemic syndromes.
Circulation.
2003;
107
2307-2312
-
30
Look K A, Sahud M, Flaherty S, Zehnder J L.
Heparin‐induced platelet aggregation vs platelet factor 4 enzyme‐linked immunosorbent assay in the diagnosis of heparin‐induced thrombocytopenia‐thrombosis.
Am J Clin Pathol.
1997;
108
78-82
-
31
Walenga J M, Jeske W P, Fasanella A R, Wood J J, Bakhos M.
Laboratory tests for the diagnosis of heparin‐induced thrombocytopenia.
Semin Thromb Hemost.
1999;
25(suppl 1)
43-49
-
32
Vun C M, Evans S, Chesterman C N.
Anti-PF4-heparin immunoglobulin G is the major class of heparin‐induced thrombocytopenia antibody: findings of an enzyme‐linked immunofiltration assay using membrane‐bound hPF4-heparin.
Br J Haematol.
2001;
112
69-75
-
33
Untch B, Ahmad S, Jeske W P et al..
Prevalence, isotype, and functionality of antiheparin‐platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin‐induced thrombocytopenia. The pathogenic role of IgG.
Thromb Res.
2002;
105
117-123
-
34
Lindhoff-Last E, Gerdsen F, Ackermann H, Bauersachs R.
Determination of heparin‐platelet factor 4-IgG antibodies improves diagnosis of heparin‐induced thrombocytopenia.
Br J Haematol.
2001;
113
886-890
-
35
Amiral J, Bridey F, Dreyfus M et al..
Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin‐induced thrombocytopenia.
Thromb Haemost.
1992;
68
95-96
-
36
Amiral J, Bridey F, Wolf M et al..
Antibodies to macromolecular platelet factor 4-heparin complexes in heparin‐induced thrombocytopenia: a study of 44 cases.
Thromb Haemost.
1995;
73
21-28
-
37
Izban K F, Lietz H W, Hoppensteadt D A et al..
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin‐induced thrombocytopenia.
Semin Thromb Hemost.
1999;
25(suppl 1)
51-56
-
38
Arepally G, Reynolds C, Tomaski A et al..
Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin‐induced thrombocytopenia.
Am J Clin Pathol.
1995;
104
648-654
-
39
Newman P M, Swanson R L, Chong B H.
Heparin‐induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross‐reactivity with low molecular weight heparin and heparinoid.
Thromb Haemost.
1998;
80
292-297
-
40
Meyer O, Salama A, Pittet N, Schwind P.
Rapid detection of heparin‐induced platelet antibodies with particle gel immunoassay (ID‐HPF4).
Lancet.
1999;
354
1525-1526
-
41
Eichler P, Raschke R, Lubenow N, Meyer O, Schwind P, Greinacher A.
The new ID-heparin/PF4 antibody test for rapid detection of heparin‐induced antibodies in comparison with functional and antigenic assays.
Br J Haematol.
2002;
116
887-891
-
42
Alberio L, Kimmerle S, Baumann A, Taleghani B M, Biasiutti F D, Lämmle B.
Rapid determination of anti‐heparin/platelet factor 4 antibody titers in the diagnosis of heparin‐induced thrombocytopenia.
Am J Med.
2003;
114
528-536
-
43
Tazzari P L, Ricci F, Vitale M et al..
Heparin‐induced thrombocytopenia: detection of antiheparin/PF4 antibodies by means of heparin/PF4-coated beads and flow cytometry.
Transfus Med.
2002;
12
193-198
-
44
Wang L, Huhle G, Malsch R, Hoffmann U, Song X, Harenberg J.
Determination of heparin‐induced IgG antibody by fluorescence‐linked immunofiltration assay (FLIFA).
J Immunol Methods.
1999;
222
93-99
-
45
Warkentin T E.
Heparin‐induced thrombocytopenia: pathogenesis and management.
Br J Haematol.
2003;
121
535-555
-
46
Refaai M A, Laposata M, Van Cott E M.
Clinical significance of a borderline titer in a negative ELISA test for heparin‐induced thrombocytopenia.
Am J Clin Pathol.
2003;
119
61-65
-
47
Rugeri L, Bauters A, Trillot N et al..
Hemostasis and thrombosis: clinical usefulness of combined use of platelet aggregation test and anti PF4-H antibodies ELISA test for the diagnosis of heparin‐induced thrombocytopenia.
Hematology.
1999;
4
367-372
-
48
Walenga J M, Jeske W P, Fasanella A R, Wood J J, Ahmad S, Bakhos M.
Laboratory diagnosis of heparin‐induced thrombocytopenia.
Clin Appl Thromb Hemost.
1999;
5(suppl 1)
S21-S27
-
49
Pouplard C, Amiral J, Borg J Y, Laporte-Simitsidis S, Delahousse B, Gruel Y.
Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin‐platelet factor 4 enzyme‐linked immunosorbent assay for diagnosis of heparin‐induced thrombocytopenia.
Am J Clin Pathol.
1999;
111
700-706
Dr.
John L FrancisPh.D.
Florida Hospital Center for Hemostasis and Thrombosis
2501 North Orange Avenue, Suite 786, Orlando, FL 32804
Email: john.francis@flhosp.org
